港股異動 | 醫脈通(2192.HK)繼續反彈 5日累計漲幅達30%
格隆匯3月1日丨醫脈通(2192.HK)續升超7%,5日累計反彈30%,日前曾創下歷史低價。現報12.34港元,暫成交2242萬港元,總市值88億港元。公司近期獲股東FIL Limited在場內持續增持股份,共涉資4001.61萬港元,持股比例由5.87%增持至6.16%。投資機構連續加倉,充分説明醫脈通的市場實力。據悉,公司將開展服務於I-IV期臨牀試驗的CRO一站式服務,為製藥及醫療器械公司和醫師,提供從臨牀研究醫學策略端到臨牀成果交付端的全生命週期服務。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.